These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11757558)

  • 1. Listed chemicals; establishment of non-regulated transactions in anhydrous hydrogen chloride. Final rule confirmation.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2001 Aug; 66(159):42944-6. PubMed ID: 11757558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exemption of chemical mixtures. Final rule.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Mar; 72(47):10925-8. PubMed ID: 17450656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of red phosphorus, white phosphorus and hypophosphorous acid (and its salts) as list I chemicals; exclusions and waivers. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37411-4. PubMed ID: 12836650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Mar; 67(60):14853-62. PubMed ID: 11922057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(133):39611-4. PubMed ID: 18850676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of the Methamphetamine Anti-Proliferation Act; thresholds for retailers and for distributors required to submit mail order reports; changes to mail order reporting requirements. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Oct; 68(194):57799-804. PubMed ID: 14535265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of thresholds for the List I chemicals pseudoephedrine and phenylpropanolamine. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2010 Jul; 75(129):38915-22. PubMed ID: 20608288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retail sales of scheduled listed chemical products; self-certification of regulated sellers of scheduled listed chemical products. Interim final rule with request for comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2006 Sep; 71(186):56008-27. PubMed ID: 17017470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of the Methamphetamine Production Prevention Act of 2008. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2011 Dec; 76(231):74696-9. PubMed ID: 22145189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 May; 68(84):23195-206. PubMed ID: 12725239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Special surveillance list of chemicals, products, materials and equipment used in the clandestine production of controlled substances or listed chemicals. Drug Enforcement Administration (DEA), Justice. Final notice.
    Fed Regist; 1999 May; 64(92):25910-2. PubMed ID: 10558537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the regulation of iodine crystals and chemical mixtures containing over 2.2 percent iodine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Jul; 72(126):35920-31. PubMed ID: 17910137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicaid program; time limitation on record keeping requirements under the drug rebate program. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Jan; 69(3):508-14. PubMed ID: 14968795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exempt chemical mixtures containing gamma-butyrolactone. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Jun; 75(124):37301-7. PubMed ID: 20608286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Registration and reregistration application fees. Final rule; remanded for further notice and comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 1996 Dec; 61(251):68624-6. PubMed ID: 12192680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Interim rule with request for comments.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Apr; 72(77):20039-47. PubMed ID: 17520757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Import and production quotas for certain List I chemicals. Interim final rule with request for comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Jul; 72(131):37439-53. PubMed ID: 17674492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designation of Alpha-Phenylacetoacetonitrile (APAAN), a Precursor Chemical Used in the Illicit Manufacture of Phenylacetone, Methamphetamine, and Amphetamine, as a List I Chemical. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2017 Jul; 82(134):32457-61. PubMed ID: 28715162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2008 May; 73(100):29685-8. PubMed ID: 18605404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.